Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications

Clinical Infectious Diseases

Volumn 56, Issue 8, 2013, Pages 1085-1093

  Irwin, Michael R ^a   Levin, Myron J ^b   Laudenslager, Mark L ^b   Olmstead, Richard ^a   Lucko, Anne ^c   Lang, Nancy ^b   Carrillo, Carmen ^a   Stanley, Harold A ^c   Caulfield, Michael J ^d   Weinberg, Adriana ^b   Chan, Ivan S F ^d   Clair, Jim ^d   Smith, Jeff G ^d   Marchese, R D ^d   Williams, Heather M ^c   Beck, Danielle J ^c   McCook, Patricia T ^c   Zhang, Jane H ^e   Johnson, Gary ^e   Oxman, Michael N ^c,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Department of Veterans   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

cellular immunity; elderly; herpes zoster; major depression; varicella zoster virus

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; VARICELLA ZOSTER VACCINE;

ADAPTIVE IMMUNITY; AGED; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VARICELLA ZOSTER VIRUS;

AGED; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; VACCINATION;

EID: 84875685408     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1208     Document Type: Article

References (31)

1. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam RCohrs RJ. Neurologic complications of the reactivation of varicellazoster virus. N Engl J Med 2000; 342:635-45. (Pubitemid 30118417)
2. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340-6.
3. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58:9.
4. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010; 51:197-213.
5. Weinberg A, Zhang JH, Oxman MN, et al. Veterans Affairs Cooperative Studies Program Shingles Prevention Study. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068-77.
6. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005; 352:2266-7. (Pubitemid 40740549)
7. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Cur Top Microbiol Immunol 2010; 342:341-57.
8. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4:26-33. (Pubitemid 38057055)
9. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20:748-53. (Pubitemid 41141008)
10. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurol 1995; 45:S41-6. (Pubitemid 26163686)
11. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
12. Levin MJ, Oxman MN, Zhang JH, et al. Veterans Affairs Cooperative Studies Program Shingles Prevention Study I. Varicella-zoster virusspecific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35. (Pubitemid 351417005)
13. Irwin MR, Levin MJ, Carrillo C, et al. Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain Behav Immun 2011; 25:759-66.
14. Schmader KE, Studenski S, MacMillan J, Grufferman S, Cohen HJ. Are stressful life events risk factors for herpes zoster? Am J Geriatr Soc 1990; 38:1188-95.
15. Schmader K, George LK, Burchett BM, Hamilton JD, Pieper CF. Race and stress in the incidence of herpes zoster in older adults. J Am Geriatr Soc 1998; 46:973-7. (Pubitemid 28374075)
16. Alexopoulos GS. Depression in the elderly. Lancet 2005; 365: 1961-70. (Pubitemid 40797508)
17. Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult: criterion validity of the 10-item Center for Epidemiological Studies Depression Scale (CES-D). Arch Intern Med 1999; 159:1701-4. (Pubitemid 29379131)
18. von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidem 1992; 45:197-203.
19. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV axis I disorders - patient edition, version 2.0. New York: New York State Psychiatric Institute, 1996.
20. Beck AT, Steer RA, Brown GK. Beck depression inventory manual. 2nd ed. San Antonio, TX: Psychological Corporation, 1996.
21. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28:193-213. (Pubitemid 19144991)
22. Hayward AR. In vitro measurement of human T cell responses to varicella zoster virus antigen. Arch Virol Suppl 2001; (suppl):143-9. (Pubitemid 33760026)
23. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001; 8:871-9. (Pubitemid 32868299)
24. Hammond O, Wang Y, Green T, et al. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella- zoster virus (VZV) antibody detection. J Med Virol 2006; 78: 1679-87. (Pubitemid 44672513)
25. Cohen S, Miller GE, Rabin BS. Psychological stress and antibody response to immunization: a critical review of the human literature. Psychosom Med 2001; 63:7-18. (Pubitemid 32125352)
26. Charney DS, Nemeroff CB, Lewis L, et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 2002; 59:262-70. (Pubitemid 34212503)
27. Thase ME. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 2003; 64(suppl 2):3-7. (Pubitemid 36231841)
28. Evans DL, Lynch KG, Benton T, et al. Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killercell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol Psychiatry 2008; 63:899-905. (Pubitemid 351458446)
29. Tucker P, Ruwe WD, Masters B, et al. Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. Biol Psychiatry 2004; 56:121-8. (Pubitemid 38844787)
30. Pacheco R, Riquelme E, Kalergis AM. Emerging evidence for the role of neurotransmitters in the modulation of T cell responses to cognate ligands. CNS Agents Medicin Chem 2010; 10:65-83.
31. Basu B, Sarkar C, Chakroborty D, et al. D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in Jurkat T leukemic cells. J Biol Chem 2010; 285:27026-32.